Per Capita Funding Raised Again For China New Rural Cooperative Medical System
This article was originally published in PharmAsia News
Chinese authorities unveiled 2013 fiscal year missions for the New Rural Cooperative Medical System, raising the per capita subsidy from RMB 240 to RMB 280 and premiums from RMB 60 to RMB 70, bringing per capita annual funds to RMB 340.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.